Your browser doesn't support javascript.
loading
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.
Zaidi, Shane; Blanchard, Miran; Shim, Kevin; Ilett, Elizabeth; Rajani, Karishma; Parrish, Christopher; Boisgerault, Nicolas; Kottke, Tim; Thompson, Jill; Celis, Esteban; Pulido, Jose; Selby, Peter; Pandha, Hardev; Melcher, Alan; Harrington, Kevin; Vile, Richard.
Afiliação
  • Zaidi S; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Targeted Therapy Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK.
  • Blanchard M; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Shim K; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Ilett E; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Targeted and Biological Therapies Group, Leeds Institute of Cancer and Pathology, St. James' University Hospital, Leeds, UK.
  • Rajani K; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Parrish C; Targeted and Biological Therapies Group, Leeds Institute of Cancer and Pathology, St. James' University Hospital, Leeds, UK.
  • Boisgerault N; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Kottke T; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Thompson J; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Celis E; Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, Georgia, USA.
  • Pulido J; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Selby P; Targeted and Biological Therapies Group, Leeds Institute of Cancer and Pathology, St. James' University Hospital, Leeds, UK.
  • Pandha H; Leggett Building, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
  • Melcher A; Targeted and Biological Therapies Group, Leeds Institute of Cancer and Pathology, St. James' University Hospital, Leeds, UK.
  • Harrington K; Targeted Therapy Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK.
  • Vile R; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Targeted and Biological Therapies Group, Leeds Institute of Cancer and Pathology, St. James' University Hospital, Leeds, UK; Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: vile.richard@ma
Mol Ther ; 23(5): 845-856, 2015 May.
Article em En | MEDLINE | ID: mdl-25544599
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma / Mutação Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma / Mutação Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article